Under pressure over its pricing of insulin, Eli Lilly (LLY) on Sunday issued a report in which it claims that the price it was paid for a key diabetes treatment fell by 8.1 percent over the past five years, after subtracting rebates and other discounts.

Specifically, the net price for Humalog, after accounting for those givebacks, was $135 a patient per month last year, down from $147 in 2014. Meanwhile, the average list — or wholesale — price during that same period increased 51.9 percent to $594 per patient each month.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’d like to know instead what they made per patient in 2005 or even better in 2001 (before the Medicare drug benefit was passed).

    Even if it is the fact (which we can’t confirm) that it’s slightly less per patient per month than in 2014, I’ll bet it’s way higher than in the past and for a very cheap drug in terms of making it.

    They so feel they have a right to make more on every patient every year on every drug that they think this vindicates them!!

    And, as Adam Fein points out, since many uninsured patients DO pay much more it doesn’t address what this does TO patients and their health.

  • Perfect illustration of the gross-to-net bubble. Too many patients pay full price for essential drugs that are sold to insurers and PBMs at deep discounts.

Your daily dose of news in health and medicine

Privacy Policy